These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9915294)

  • 1. Technology assessment: relationship to coverage issues--a case for temporary coverage decisions.
    Diamond LH
    Am J Kidney Dis; 1999 Jan; 33(1):208-10. PubMed ID: 9915294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The review process used by US health care plans to evaluate new medical technology for coverage.
    Steiner CA; Powe NR; Anderson GF; Das A
    J Gen Intern Med; 1996 May; 11(5):294-302. PubMed ID: 8725978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology assessment, coverage decisions, and conflict: the role of guidelines.
    Sheingold SH
    Am J Manag Care; 1998 Sep; 4 Spec No():SP117-25. PubMed ID: 10185988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insurance coverage for experimental technologies.
    Steinberg EP; Tunis S; Shapiro D
    Health Aff (Millwood); 1995; 14(4):143-58. PubMed ID: 8690340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXPANDING EVIDENCE-BASED TECHNOLOGY ASSESSMENT FOR COVERAGE IN WASHINGTON STATE.
    Landaas EJ; Franklin G; Thompson J; Lessler D; Morse J; Mootz R; Hammond SG; Sullivan SD
    Int J Technol Assess Health Care; 2016 Jan; 32(3):140-6. PubMed ID: 27491675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage decisions in a high-tech world.
    Nazametz P
    Bus Health; 1987 Aug; 4(10):12-3. PubMed ID: 10282932
    [No Abstract]   [Full Text] [Related]  

  • 9. Technology coverage decisions by health care plans and considerations by medical directors.
    Steiner CA; Powe NR; Anderson GF; Das A
    Med Care; 1997 May; 35(5):472-89. PubMed ID: 9140336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis.
    Eddy D
    Health Aff (Millwood); 2007; 26(4):w500-15. PubMed ID: 17580317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment and private payers's coverage of personalized medicine.
    Trosman JR; Van Bebber SL; Phillips KA
    Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence, appropriateness, and technology assessment in cardiology: a case study of computed tomography.
    Redberg RF
    Health Aff (Millwood); 2007; 26(1):86-95. PubMed ID: 17211017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice.
    Abelson J; Giacomini M; Lehoux P; Gauvin FP
    Health Policy; 2007 Jun; 82(1):37-50. PubMed ID: 16996637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions.
    Fox DM
    Health Aff (Millwood); 2005; 24(1):114-22. PubMed ID: 15647221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.
    Brügger U; Horisberger B; Ruckstuhl A; Plessow R; Eichler K; Gratwohl A
    BMJ Open; 2015 Mar; 5(3):e007021. PubMed ID: 25818273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada.
    Giacomini M; Miller F; Browman G
    Int J Technol Assess Health Care; 2003; 19(2):301-16. PubMed ID: 12862188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and evidence evaluation as criteria for coverage policy.
    Garber AM
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-284-96. PubMed ID: 15451997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012.
    Brügger U; Ruckstuhl A; Horisberger B; Gratwohl A
    Int J Technol Assess Health Care; 2014 Jul; 30(3):253-9. PubMed ID: 25100035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The scientific basis for coverage decisions by third-party payers.
    Towery OB; Perry S
    JAMA; 1981 Jan; 245(1):59-61. PubMed ID: 6776306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employer coverage of experimental medical procedures.
    Mora J
    Health Cost Manage; 1986; 3(5):17-25. PubMed ID: 10279242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.